IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-05762991.html

TRIPS, pharmaceutical patents, and generic competition in India

Author

Listed:
  • Margaret Kyle

    (CEDP i3 - Centre d'Economie et de Décision Publique i3 (anciennement CERNA i3) - Mines Paris - PSL (École nationale supérieure des mines de Paris) - PSL - Université Paris Sciences et Lettres - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique)

  • Bhaven Sampat
  • Kenneth Shadlen

Abstract

Introduction India introduced pharmaceutical patents in response to the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. Previous studies that focused on older drugs showed limited effects of patents on India's generic market. We examine how a transitional TRIPS provision, which made patents with first global filing (priority) before 1995 ineligible, affected the likelihood of drugs obtaining strong "primary" patents in India, and the subsequent effects on generic competition. Methods We determined the primary patent priority year (PPPYear) for drugs approved in the United States 1995-2017. For each drug, we gathered Indian patent information and recorded the level of generic competition five years from launch. Results Primary patents are much more common after PPPYear 1995. Indian generic competition falls approximately 40% after this cutoff, especially for drugs with Indian primary patents. Conclusion Post-1995 PPPYear drugs are more likely to have primary patents and face less generic competition in India. These drugs now constitute most approvals in India and better reflect the long-run impact of TRIPS than drugs previously examined. The prevalence of drugs in India with primary patents and less competition has important implications for global access to medicines.

Suggested Citation

  • Margaret Kyle & Bhaven Sampat & Kenneth Shadlen, 2026. "TRIPS, pharmaceutical patents, and generic competition in India," Post-Print hal-05762991, HAL.
    • Handle: RePEc:hal:journl:hal-05762991
    DOI: 10.1093/haschl/qxaf239
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a
    for a similarly titled item that would be available.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-05762991. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.